Anthem Biosciences IPO GMP In Focus As Mainboard Issue Opens Next Week — Check Key Details
The price band for the Anthem Biosciences IPO has been fixed between Rs 540 and Rs 570 per share.
Anthem Biosciences Ltd. is set to launch its initial public offering next week. The company aims to raise over Rs 3,000 crore from the primary market through its IPO.
Anthem Biosciences specialises in contract manufacturing of drugs for various biotech firms and large pharmaceutical companies.
Investors who want to bid for shares in the IPO can check the following details before making an investment call.
Anthem Biosciences IPO GMP Today
According to InvestorGain, the grey market premium (GMP) for the Anthem Biosciences IPO stood at Rs 107 as of 9:31 a.m. on July 11. The latest GMP indicates a listing price of Rs 677 apiece at a premium of 18.77% against the upper limit of IPO the price band.
Note: GMP does not represent official data and is based on speculation.
Anthem Biosciences IPO: Key Details
Anthem Biosciences IPO is a book-building issue of Rs 3,395 crore, comprising entirely an offer-for-sale (OFS) of 5.96 crore shares.
The price band for the mainboard issue has been fixed between Rs 540 and Rs 570 per share.
To participate in the IPO, retail investors need to bid for a single lot size of 26 shares, requiring an investment of Rs 14,040. Small Non-Institutional Investors need to bid for 14 lots, amounting to an investment of Rs 2,07,480. Big Non-Institutional Investors can participate in the IPO by bidding for a minimum of 68 lots, amounting to an investment of Rs 10,07,760.
Investors can participate in the IPO subscription from July 14 to July 16. The IPO share allotment status is scheduled to be finalised on July 17. The company will transfer shares to the Demat accounts of successful bidders on July 18 and refunds for non-allottees will be done on the same day.
Shares of Anthem Biosciences are proposed to be listed on the BSE and NSE on July 21.
A maximum of 50% of the net issue is reserved for Qualified Institutional Buyers (QIBs). At least 35% of the net issue will be offered to retail investors and a minimum of 15% will be reserved for Non-Institutional Investors.
JM Financial Ltd. is the book-running lead manager of the Anthem Biosciences IPO. KFin Technologies Ltd. is the registrar for the issue.
Use Of Proceeds
Anthem Biosciences will not receive any proceeds from the IPO. The shareholders selling the shares will get the proceeds.
About Anthem Biosciences
According to its website, Anthem Biosciences is a Contract Research and Innovation Service Provider (CRISP). It produces drugs with an emphasis on biological and chemistry-based products.
Financials
The company reported a 22.86% year-on-year (YoY) increase in profit after tax (PAT) to Rs 451.26 crore in FY25 from Rs 367.31 crore in FY24. Total revenue from operations rose 29.96% YoY to Rs 1,844.55 crore in FY25 from Rs 1,419.37 crore in FY24.
Disclaimer: Investments in initial public offerings are subject to market risks. Please consult with financial advisors and read the red herring prospectus thoroughly before placing bids.
